Results 21 to 30 of about 276,897 (341)

Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors [PDF]

, 2016
PURPOSE: Subsets of pituitary tumors exhibit an aggressive clinical courses and recur despite surgery, radiation, and chemotherapy. Because modulation of the immune response through inhibition of T-cell checkpoints has led to durable clinical responses ...
Agar, Nathalie Y. R., Bi, Wenya Linda, Du, Ziming, Dunn, Gavin P, Dunn, Ian F, Fecci, Peter E, Freeman, Gordon J, Greenwald, Noah F, Kaiser, Ursula B, Laws, Edward R, Jr, Mei, Yu, Reardon, David A, Santagata, Sandro, Woodmansee, Whitney W   +13 more
core   +3 more sources

Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients. [PDF]

, 2020
Chemotherapy and checkpoint inhibitor immunotherapies are increasingly used in combinations. We determined associations between the presence of anti-PD-1/PD-L1 therapeutic biomarkers and protein markers of potential chemotherapy response.
Arguello, David, Barkauskas, Donald A, Gatalica, Zoran, Kurzrock, Razelle, Nikanjam, Mina, Swensen, Jeff   +5 more
core   +2 more sources

Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave

Biomedicines, 2021
Programmed death-ligand 1 (PD-L1) is one of the most classic immune checkpoint molecules. Cancer cells express PD-L1 to inhibit the activity of effector T cells’ cytotoxicity through programmed death 1 (PD-1) engagement in exposure to inflammatory ...
Xinfang Yu, Wei Li, Ken H. Young, Yong Li   +3 more
doaj   +1 more source

Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti–PD-L1 Antibodies [PDF]

Cancer Research, 2015
Abstract Antibodies that block the interaction between programmed death ligand 1 (PD-L1) and PD-1 have shown impressive antitumor activity. Patients with tumors expressing PD-L1 are most likely to respond to this treatment. The aim of our study was to develop a noninvasive imaging technique to determine tumor PD-L1 expression in vivo ...
Heskamp, S., Hobo, W.A., Molkenboer-Kuenen, J.D.M., Molkenboer-Kuenen, J.D.M., Olive, D., Oyen, W.J.G., Dolstra, H., Boerman, O.C.   +7 more
openaire   +3 more sources

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. [PDF]

, 2020
Although immunotherapies have achieved remarkable salutary effects among subgroups of advanced cancers, most patients do not respond. We comprehensively evaluated biomarkers associated with the "cancer-immunity cycle" in the pan-cancer setting in order ...
Dressman, Devin, Eskander, Ramez, Glenn, Sean T, Goodman, Aaron, Ikeda, Sadakatsu, Kato, Shumei, Kumaki, Yuichi, Kurzrock, Razelle, Lee, Suzanna, Lenzo, Felicia L, Morrison, Carl, Nikanjam, Mina, Okamura, Ryosuke, Papanicolau-Sengos, Antonios   +13 more
core   +1 more source

Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab [PDF]

, 2016
Controversial results on the predictive value of programmed death ligand 1 (PD-L1) status in lung tumor tissue for response to immune checkpoint inhibitors do not allow for any conclusive consideration.
Caponnetto, Salvatore, Cortesi, Enrico, DEL BENE, Gabriella, Gandini, Orietta, Gazzaniga, Paola, Gradilone, Angela, Longo, F, Mancini, Marialaura, Mastromartino, M, Nicolazzo, Chiara, Prete, ALESSANDRA ANNA, Raimondi, Cristina   +11 more
core   +1 more source

The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC [PDF]

, 2017
Background: Immune checkpoint inhibitors improve outcomes compared with chemotherapy in lung cancer. Tumor PD-L1 receptor expression is being studied as a predictive biomarker. The objective of this study was to assess the cost-effectiveness and economic
Abdel-Rahman, Aguiar, Borghaei, Brahmer, Calhoun, Chen, Dent, Domingues, Doyle, Ferlay, Goeree, Hanahan, Herbst, Herbst, Huang, Hurvitz, Masters, Matter-walstra, Moro-Sibilot, Nafees, Passiglia, Petitti, Rittmeyer, Siegel, Stokes, Tartari   +25 more
core   +3 more sources

Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1

Cellular & Molecular Immunology, 2022
Abstract PD-L1 + tumor-derived extracellular vesicles (TEVs) cause systemic immunosuppression and possibly resistance to anti-PD-L1 antibody (αPD-L1) blockade. However, whether and how PD-L1 + TEVs mediate αPD-L1 therapy resistance is ...
Zhijian Cai, Jiming Chen, Jie Yang, Wenhui Wang, Danfeng Guo, Chengyan Zhang, Shibo Wang, Xinliang Lu, Xiaofang Huang, Pingli Wang, Gensheng Zhang, Jing Zhang, Jianli Wang   +12 more
openaire   +2 more sources

PD‐L1 methylation regulates PD‐L1 expression and is associated with melanoma survival [PDF]

Pigment Cell & Melanoma Research, 2018
AbstractThe aim of this study is to determine the significance of programmed death ligand 1 (PD‐L1 or CD274) methylation in relation to PD‐L1 expression and survival in melanoma. Despite the clinical importance of therapies targeting the PD‐1/PD‐L1 immune checkpoint in melanoma, factors regulating PD‐L1 expression, including epigenetic mechanisms, are ...
Goran Micevic, Durga Thakral, Meaghan McGeary, Marcus W. Bosenberg   +3 more
openaire   +2 more sources

Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer. [PDF]

, 2018
Metastatic non-small cell lung cancer (NSCLC) is a highly fatal and immunogenic malignancy. Although the immune system is known to recognize these tumor cells, one mechanism by which NSCLC can evade the immune system is via overexpression of programmed ...
Che, James, Dhar, Manjima, Di Carlo, Dino, Elashoff, David, Garon, Edward B, Goldman, Jonathan W, Grogan, Tristan, Kulkarni, Rajan P, Matsumoto, Melissa, Sollier Christen, Elodie, Wong, Jessica   +10 more
core   +3 more sources